logo
  

International Paper Says No Comments On Rumors Amid Strategic Initiatives And DS Smith Merger Plans

International Paper (IP) said it adheres to its standard policy of refraining from commenting on rumors or speculation circulating in recent media reports. Under the leadership of new CEO Andy Silvernail, the IP team is actively implementing business strategies and pursuing commercial and cost improvement initiatives across its portfolio.

International Paper said it remains committed to completing its previously announced merger with DS Smith.

Earlier today, Reuters reported that International Paper has been approached by Suzano with an offer to buy the Memphis paper conglomerate for about $15 billion.
If the companies move ahead with the deal, it could disrupt International Paper's pending acquisition of U.K. company DS Smith. IP outbid rival Monty Plc for the deal.

Last month, International Paper and DS Smith reached agreement on the terms of a recommended all-share combination. The terms of the combination values each DS Smith share at 415 pence per share, and will result in IP issuing 0.1285 shares for each DS Smith share, resulting in pro forma ownership of 66.3 percent for IP shareholders and 33.7 percent for DS Smith shareholders, implying a transaction value of approximately $9.9 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT